<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Penicillin V potassium (oral): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Penicillin V potassium (oral): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Penicillin V potassium (oral): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9751" href="/d/html/9751.html" rel="external">see "Penicillin V potassium (oral): Drug information"</a> and <a class="drug drug_patient" data-topicid="10960" href="/d/html/10960.html" rel="external">see "Penicillin V potassium (oral): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867892"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Pen-VK</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1049295"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Penicillin</span></li></ul></div>
<div class="block dop drugH1Div" id="F207870"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing: </b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate infection: Oral: 25 to 50 mg/kg/day in divided doses every 6 hours; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax (penicillin-susceptible strains) </b>(alternative agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis, exposure to aerosolized spores: </i>Oral: 50 to 75 mg/kg/day in divided doses every 6 to 8 hours for 60 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous, without systemic involvement:</i> Oral: 50 to 75 mg/kg/day in divided doses every 6 to 8 hours. Duration: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related event/exposure to aerosolized spore.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic, oral step-down therapy:</i> Oral: 50 to 75 mg/kg/day in divided doses every 6 to 8 hours to complete 60-day course; should be used as a component of combination therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b7218be5-93fa-4043-82fa-60a9dce6677d">Fusospirochetosis, mild to moderately severe infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fusospirochetosis (Vincent infection), </b>
<b>mild to moderately severe infections:</b> Children ≥12 years and Adolescents: Oral: 250 to 500 mg every 6 to 8 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61bb2678-197f-43d3-b1b8-93695c10abd0">Pneumonia, community-acquired; Group A Streptococcus, mild infection or step-down therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired; Group A </b>
<i>
<b>Streptococcus</b></i>
<b>, mild infection or step-down therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 50 to 75 mg/kg/day in divided doses 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>); <b>Note:</b> Usual adult maximum daily dose is 2,000 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dfbc3246-1bad-4350-b592-9b67ea2ffd98">Pneumococcal infection prophylaxis for anatomic or functional asplenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumococcal infection prophylaxis for anatomic or functional asplenia (eg, sickle cell disease [SCD])</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10920169','lexi-content-ref-3086721','lexi-content-ref-NHLBI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10920169','lexi-content-ref-3086721','lexi-content-ref-NHLBI.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants (as soon as SCD diagnosed or asplenic) and Children &lt;3 years: Oral: 125 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years: Oral: 250 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Current guidelines recommend discontinuation of prophylaxis at 5 years of age unless the patient has experienced invasive pneumococcal infection or splenectomy; data regarding when to discontinue are limited and practice varies; decision should be made on a case-by-case basis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23193095','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23193095','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b84b887-3faf-4b9d-bc9d-ccfa75e1d576">Pneumococcal infection prophylaxis, patients post-hematopoietic cell transplant with chronic graft-versus-host disease or low IgG levels</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumococcal infection prophylaxis, patients post-hematopoietic cell transplant with chronic graft-versus-host disease or low IgG levels </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>):<b> Note:</b> Use only in areas where incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> is low.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months and Children ≤3 years: Oral: 125 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;3 years: Oral: 250 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 250 to 500 mg twice daily or 500 to 1,000 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f2098d-7a15-436e-bc6b-422791b57466">
<i>Streptococcus</i>, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pharyngitis/tonsillitis: </i>Limited data available in &lt;12 years of age:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≤27 kg: Oral: 250 mg every 8 to 12 hours for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689','lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689','lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;27 kg and Adolescents: Oral: 500 mg every 8 to 12 hours for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689','lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689','lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rheumatic fever, secondary prevention:</i> Limited data available in &lt;12 years of age: <b>Note:</b> IM benzathine penicillin G is preferred, except in patients who are at elevated risk of death from cardiovascular compromise with IM penicillin (eg, severe valvular disease, ventricular ejection fraction &lt;50%, NYHA class III/IV symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35049336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35049336'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: 250 mg twice daily. Duration depends on risk factors including number of previous attacks, risk of exposure to Group A streptococcal infections, age, and presence of valvular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic carriage:</i> Limited data available: <b>Note: </b>Most individuals with chronic carriage do not require antibiotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: 50 mg/kg/day in 4 divided doses for 10 days; maximum dose: 500 mg/dose; give in combination with oral rifampin for the last 4 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51152531"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; excretion is prolonged in patients with kidney impairment.</p></div>
<div class="block dohp drugH1Div" id="F51152532"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F207860"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9751" href="/d/html/9751.html" rel="external">see "Penicillin V potassium (oral): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60e9d2ac-8a42-4447-963b-6e516db3e471">Actinomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinomycosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For initial therapy of mild infection or step-down therapy following parenteral treatment of severe infection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg to 1 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brook.2020','lexi-content-ref-8339619','lexi-content-ref-9636842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brook.2020','lexi-content-ref-8339619','lexi-content-ref-9636842'])">Ref</a></span>). Optimal duration is uncertain; some experts suggest total durations of 2 to 6 months for mild infection and 6 to 12 months for severe or extensive infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brook.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brook.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax (alternative agent for penicillin-susceptible strains) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations. A high index of suspicion for emergent beta-lactam resistance during therapy is warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Inhalational exposure (postexposure prophylaxis):</b>
<b>Oral:</b> 500 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>); duration depends on anthrax vaccine status and series completion, age, immune status, and pregnancy/breastfeeding status; for those who have not previously received anthrax vaccine, duration ranges from 42 to 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>). <b>Note:</b> Anthrax vaccine should also be administered to exposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cutaneous, without systemic involvement, treatment: Oral:</b> 500 mg every 6 hours; duration is 7 to 10 days after naturally acquired infection and 60 days following biological weapon–related event. <b>Note:</b> Patients with extensive edema or cutaneous lesions of the head or neck should be treated with a parenteral regimen recommended for systemic infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf0996fd-b1e3-4d3a-a9a0-7f24593cec52">Bite wound infection, prophylaxis of high-risk bite or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, prophylaxis of high-risk bite or treatment (animal or human bite) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg 4 times daily as part of an appropriate combination regimen. For prophylaxis, duration is 3 to 5 days; for treatment of established infection, duration is typically 5 to 14 days and varies based on clinical response and patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2020a','lexi-content-ref-Baddour.2020b','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2020a','lexi-content-ref-Baddour.2020b','lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="43d56922-b99b-4f35-b80e-4c4789e9f020">Diphtheria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diphtheria (adjunctive therapy with antitoxin) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg every 6 hours to complete a total treatment course of 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2017'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13fffee0-1f22-4047-ad66-3a4e6e6716e0">Gingivitis, acute simple, plaque-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gingivitis, acute simple, plaque-associated:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve systemic therapy for patients with rapidly progressive disease, severe pain, or immunocompromising conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg every 6 to 8 hours in combination with metronidazole for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="39ad6939-0f9e-485c-be70-f904e69c847c">Meningococcal prophylaxis in patients with complement deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal prophylaxis in patients with complement deficiency (eg, due to C5 inhibitor therapy) (off-label use):</b> Limited data:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg twice daily in addition to meningococcal vaccination; for those taking a C5 inhibitor, administer meningococcal vaccination 2 weeks prior to initiation of C5 inhibitor therapy and give penicillin V potassium for the duration of C5 inhibitor therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Apicella.2020','lexi-content-ref-28808592','lexi-content-ref-Liszewski.2020','lexi-content-ref-28704351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Apicella.2020','lexi-content-ref-28808592','lexi-content-ref-Liszewski.2020','lexi-content-ref-28704351'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="164222d6-88e9-415d-ad0e-8fe154087ff0">Pneumococcal prophylaxis in patients at high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumococcal prophylaxis in patients at high risk (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For select patients at high risk (eg, patients with functional or anatomic asplenia, sickle cell disease, allogeneic hematopoietic cell transplant recipients with chronic graft-vs-host disease or hypogammaglobulinemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-27925427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-27925427'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 250 to 500 mg twice daily; duration varies based on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-27925427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-27925427'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b595739-8c04-4fd6-a7d4-afa7aea8d75f">Prosthetic joint infection, chronic suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection, chronic suppression (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For infection caused by beta-hemolytic streptococci, penicillin-susceptible <i>Enterococcus</i> spp., or <i>Cutibacterium </i>spp. (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg 2 to 4 times daily (IDSA [Osmon 2013]); duration depends on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="169f5d56-185b-4306-aa6c-62a3aec7a18b">Rat bite fever, uncomplicated infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rat bite fever, uncomplicated infection (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg every 6 hours following parenteral therapy to complete a total treatment course of 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-King.2020','lexi-content-ref-Washburn.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-King.2020','lexi-content-ref-Washburn.2015'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cellulitis, long-term suppression of recurrent infection (off-label use):</b>
<b>Note:</b> For patients with recurrent presumptive beta-hemolytic streptococcal cellulitis at the same anatomical site despite addressing predisposing factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 250 to 500 mg twice daily after completion of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1','lexi-content-ref-23635049']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1','lexi-content-ref-23635049'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Erysipelas, treatment of mild infection or step-down therapy after initial parenteral therapy: Oral:</b> 500 mg every 6 hours; total duration is 5 days, with extension to 14 days for slow response, severe infection, or immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Erysipeloid (localized cutaneous Erysipelothrix rhusiopathiae infection), treatment (off-label use): Oral:</b> 500 mg every 6 hours for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Reboli.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Reboli.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f2098d-7a15-436e-bc6b-422791b57466">
<i>Streptococcus</i>, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus</i>, group A:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pharyngitis: Oral:</b> 500 mg 2 to 3 times daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689','lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689','lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Secondary prophylaxis in patients with rheumatic fever (prevention of recurrent attacks) (alternative agent): Note:</b> IM benzathine penicillin G is preferred, except in patients who are at elevated risk of death from cardiovascular compromise with IM penicillin (eg, severe valvular disease, ventricular ejection fraction &lt;50%, NYHA class III/IV symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35049336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35049336'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 250 mg twice daily. Duration depends on risk factors, age, and presence of valvular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic carriage (off-label use):</b>
<b>Note:</b> Most individuals with chronic carriage do not require antimicrobial treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 500 mg 4 times daily for 10 days; add rifampin for the last 4 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3919171','lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3919171','lexi-content-ref-22965026'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990827"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Use with caution; excretion is prolonged in patients with renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50988040"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F207824"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%: Gastrointestinal: Melanoglossia, mild diarrhea, nausea, oral candidiasis, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%: Acute interstitial nephritis, anaphylaxis, convulsions, exfoliative dermatitis, fever, hemolytic anemia, hypersensitivity reaction, positive direct Coombs test, serum-sickness like reaction</p></div>
<div class="block coi drugH1Div" id="F207839"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to penicillin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F207821"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or history of sensitivity to multiple allergens.). Use with caution in asthmatic patients. If a serious reaction occurs, treatment with supportive care measures and airway protection should be instituted immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).</p></div>
<div class="block foc drugH1Div" id="F207833"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F207817"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F207842"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Penicillin V Potassium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Penicillin V Potassium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.46 - $1.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.78 - $2.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867893"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg</p></div>
<div class="block adip drugH1Div" id="F53568127"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">0.7 mEq of potassium/250 mg penicillin V; 250 mg = 400,000 units of penicillin</p></div>
<div class="block admp drugH1Div" id="F52613562"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: To enhance absorption, administer with water on an empty stomach.</p></div>
<div class="block adm drugH1Div" id="F207836"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<i>Oral:</i> Administer around-the-clock to promote less variation in peak and trough serum levels. Take on an empty stomach 1 hour before or 2 hours after meals, to enhance absorption.</p></div>
<div class="block sts drugH1Div" id="F207851"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Powder for oral solution: Store dry powder at 20°C to 25°C (68°F to 77°F). Reconstituted oral solution should be stored in refrigerator. Discard unused solution after 14 days (consult manufacturer labeling for specific recommendations).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53568293"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of mild to moderately severe susceptible bacterial infections involving the upper respiratory tract and skin and soft tissues, including pneumococcal infections, staphylococcal infections, streptococcal infections (without bacteremia); treatment of fusospirochetosis; prophylaxis of rheumatic fever and/or chorea (All indications: FDA approved in ages ≥12 years and adults); has also been used for prophylaxis of invasive pneumococcal infections in high-risk patients, treatment of community-acquired cutaneous anthrax, and treatment of community-acquired pneumonia caused by group A <i>Streptococcus</i>.</p></div>
<div class="block mst drugH1Div" id="F207884"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Penicillin may be confused with penicillAMINE</p>
<p style="text-indent:-2em;margin-left:4em;">Penicillin V potassium may be confused with penicillin G benzathine, penicillin G (parenteral/aqueous), penicillin G procaine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299843"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F207826"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guar Gum (Partially Hydrolyzed): May decrease the serum concentration of Penicillin V Potassium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F207852"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases drug absorption rate; decreases drug serum concentration. Management: Take on an empty stomach 1 hour before or 2 hours after meals around-the-clock to promote less variation in peak and trough serum levels.</p></div>
<div class="block pri drugH1Div" id="F5720583"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Penicillin crosses the placenta (Heikkilä 1994).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of penicillin V may be altered in the second and third trimester (Heikkilä 1993).</p>
<p style="text-indent:0em;margin-top:2em;">Penicillin is widely used in pregnant patients. Based on available data, penicillin is generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Dencker 2002; Heikkilä 1994; Heinonen 1977; Lamont 2014; Muanda 2017a; Muanda 2017b).</p>
<p style="text-indent:0em;margin-top:2em;">Penicillin is recommended for the management of syphilis during pregnancy. Penicillin V is not recommended for treatment; however, it may be used in the desensitization protocol so that the appropriate penicillin formulation may then be used (CDC [Workowski 2021]; Dallé 2018).</p>
<p style="text-indent:0em;margin-top:2em;">If treatment for the management of <i>Bacillus anthracis</i> is needed in pregnant patients, other agents are preferred (Meaney-Delman 2014).</p></div>
<div class="block mopp drugH1Div" id="F53568285"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">With prolonged therapy, monitor renal and hematologic function periodically; observe for change in bowel frequency; monitor for signs of anaphylaxis during first dose.</p></div>
<div class="block pha drugH1Div" id="F207820"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F207838"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: 80%.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 60% to 73% (Nathwani 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: Oral: 30 minutes (Nathwani 1993); 62 ± 14 minutes (Lindberg 1987); 112 ± 47 minutes (Heikkilä 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as unchanged drug and metabolites).</p></div>
<div class="block phksp drugH1Div" id="F51198648"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Excretion is considerably delayed.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: In neonates and young infants, excretion is considerably delayed.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time dependent, associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC), goal: ≥50% <i>f</i>T &gt; MIC (bactericidal) (Craig 1996; Craig 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in adults with normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg every 6 hours, steady state: 4.9 to 6.3 mg/L (MacGregor 1997).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i> Minimal bacterial killing continues after penicillin concentration falls below the MIC of targeted pathogen and varies based on the organism:</p>
<p style="text-indent:-2em;margin-left:6em;">Gram-positive cocci: 1.5 to 3.5 hours (Craig 1991; Garcia 1995; Zhanel 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">Gram-negative bacilli: 0 to 1.5 hours (Craig 1991; Zhanel 1991).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F207845"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Arcasin | Cliacil | Ospen | Uticillin vk | V-cil-k</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cliacil | Fenoxipen | Pen oral | Penfantil | Penicilina oral lepetit | Penicilina oral richet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Megacillin | Ospen | Pen v | Penbene | Penstad v | Star Pen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Abbocillin vk | Aspecillin vk | Cilicaine vk | L p v | Phenoxymethylpenicillin aft</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cliacil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Peni-Oral</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cliacil | Ospen | Phenocillin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Meracilina | Oracilin | Pen ve oral | Pencilin v | Penicigran</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ospen | Penicillin | Penicillin spirig | Stabicilline</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fenoximetilpenicilina | Penicilina fenox | Prevepen</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Banzatin | Benzylpenicillin v | Fen fei | Kang kou jia | Lisrei | Megacillin | Penicillin v | Penicillin v potassium | Penicillin v-k | Pin sha ding | Rui wei | Sai xin di | Sen di</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bemicilina | Erapen | Pen vee k | Penicilina v potasica</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Penbene | Pencid | V penicilin | V penicillin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Arcasin | Dura penicillin | Infectocillin | Isocillin | Ispen Rp | Ispen Saar | Ispenoral | Jenacillin v | Megacillin | P-mega-tablinen | Pen | Pen 1,5 mega 1 a pharma | Pen Mega | Pen v merck | Penbeta | Pencompren | Penhexal | Penicillat | Penicillin | Penicillin sandoz | Penicillin v | Penicillin v abz 1 mega | Penicillin v al | Penicillin v basic | Penicillin v billix | Penicillin V CT | Penicillin v dura | Penicillin v stada 1,2 mega | Penicillin v wolff</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Rapenin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cliacil | Megacilina | Ospen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Megacilina | Ospen</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Arcasin | Infectocillin | Ospen | Penicillin v | Penicillin v-ratiopharm | Phenoxymethylpenicillin | V penicillin | V-Pen | V-pen mega | Vepicombin | Vepicombin novum</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cliacil | Ospen | Star Pen</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Penilevel</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Biopen | Fenocin | Fenoxypen | Medicillin | Milcopen | Milcopen-500 | Minipen | Ospen | Penimil | Primcillin | Rocilin | V penisilliini ratiopharm | V-Pen</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Apsin vk | Crystapen v | G p v | Icipen | Ledercillin | Penicillin v | Penicillin v cox | Penicillin v kent | Penicillin vk | Penicillin vk berk | Penicillin vk cox | Phenoxymethylpenicillin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Infectocillin | Ospen</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Penicillin v | Penicillin vk | Qualipen</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ospen K | Penon | Silapen K</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ospen</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fenocin | Ospen | Penicillin | Penicillin v | Phenoxymethyl</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Kopen</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Pen Rafa VK | Rafapen | Rafapen v-k</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Crystapen v | Kaypen</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ospen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Penicillin v potassium banyu | Penicillin v potassium meiji seika | V kal k</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Elypen | Laepen v | Mil vk | Ospen | Penicillin v | Speniv | Unipen</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ospen</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Arcasin | Ospen</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Arcasin | Ospen | Phenoxymethylpenicillin | V penicillin | V Pnc</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Megacillin | Penhexal | Peni-Oral</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Arcasin | Fau penicillin | Isocillin | Ospen | V penicillin | Vepicombin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cliacil | Ospen | Phenocilline</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Pen vi k | Pentek 20 | Pota vi kin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fenocin | Ospen | Ospen Kv | Penicillin v | Penicillin vk | Safcillin V</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Greenlife penicillin v | Timec pencillin v</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fenoxymethylp</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Apocillin | Femepen | Kaavepenin | Primcillin | Rocilin | Weifapenin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fenoiximetilpenicilina potasio | Fenoxilina | Medicilina | Megacilina | Pexifep</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Megapen | Sumapen vk</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Pencin | Penicillin v | Penisol vk</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ospen | Taropen | V cylina | V penicillin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Beepen vk | Pen vee k | Penicillin v potassium | Penicillin vk | Veetids</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cliacil</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ospen 400</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cliacil | Ospen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Phenoxymethylpenicillin | V penicillin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ospen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Apocillin | Avopenin | Fenoximetylpenicillin EQL Pharma | Fenoximetylpenicillin orifarm | Fenoxypen | Kaavepenin | Kaavepenin Frukt | Peceve | Phenoxymethylpenicillin EQL | Primve | Tikacillin | Vepen</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Beapen | Fenocin | Ospen | Ospen Kv | Pencillin | Penicillin v | Penicillin vk | Penopen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cliacil | Ibaden | Kalijev fenoksimetilpenicilinat sandoz | Ospen</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ospen | Penbene | V penicilin | V Pnc</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fenocin | P cillin V | Pen v | Pen V Oral Four | Pener-v | Penicillin v | Penvedon | Penvisil | Semicillin | Servipen-v | Star-V | Suveelin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ospen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cliacil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ospen | Penicillin v</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ospen | Penicillin fau | Phenoxymethylpenicillin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agopen | Speniv</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ospen</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ospen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Betapen | Deltacillin | Len v.k. | Novo v-k | Rolab-pen-v-k | V-cil-k</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Betapen | Phenoxymethyl penicillin potassium | Speniv</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al; The National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10920169">
<a name="10920169"></a>American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. <i>Pediatrics</i>. 2000;106(2 Pt 1):362-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/10920169/pubmed" id="10920169" target="_blank">10920169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11875155">
<a name="11875155"></a>American Academy of Pediatrics. Section on Hematology/Oncology Committee on Genetics. Health supervision for children with sickle cell disease. <i>Pediatrics</i>. 2002;109(3):526-535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/11875155/pubmed" id="11875155" target="_blank">11875155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apicella.2020">
<a name="Apicella.2020"></a>Apicella M. Treatment and prevention of meningococcal infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.1">
<a name="Berbari.1"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2020a">
<a name="Baddour.2020a"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2020b">
<a name="Baddour.2020b"></a>Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834290">
<a name="31834290"></a>Bower WA, Schiffer J, Atmar RL, et al; ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. <i>MMWR Recomm Rep</i>. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/31834290/pubmed" id="31834290" target="_blank">31834290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al; Pediatric Infectious Diseases Society; Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>, 2011, 53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777226">
<a name="24777226"></a>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-e1436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/24777226/pubmed" id="24777226" target="_blank">24777226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brook.2020">
<a name="Brook.2020"></a>Brook I. Treatment of actinomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2015">
<a name="CDC.2015"></a>Centers for Disease Control and Prevention. <i>Epidemiology and Prevention of Vaccine-Preventable Diseases</i> (the "Pink Book"). 13th ed. Public Health Foundation; 2015. <a href="https://www.cdc.gov/vaccines/pubs/pinkbook/dip.html" target="_blank">https://www.cdc.gov/vaccines/pubs/pinkbook/dip.html</a>. Accessed August 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention. Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3919171">
<a name="3919171"></a>Chaudhary S, Bilinsky SA, Hennessy JL, et al. Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy. <i>J Pediatr</i>. 1985;106(3):481-486. doi:10.1016/s0022-3476(85)80687-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/3919171/pubmed" id="3919171" target="_blank">3919171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chow.1">
<a name="Chow.1"></a>Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8937847">
<a name="8937847"></a>Craig WA. Antimicrobial resistance issues of the future. <i>Diagn Microbiol Infect Dis</i>. 1996;25(4):213-217. doi:10.1016/s0732-8893(96)00162-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/8937847/pubmed" id="8937847" target="_blank">8937847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis.</i> 1998;26(1):1-10. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>Clin Microbiol Newsletter</i>. 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28859210">
<a name="28859210"></a>Dallé J, Ramos MC, Jimenez MF, Escobar FG, Antonello VS. Oral desensitization to penicillin for the treatment of pregnant women with syphilis: a successful program. Dessensibilização oral à penicilina para o tratamento da sífilis na gestação: um exemplo de experiência bem-sucedida. <i>Rev Bras Ginecol Obstet</i>. 2018;40(1):43-46. doi:10.1055/s-0037-1606274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/28859210/pubmed" id="28859210" target="_blank">28859210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol</i>. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12047410">
<a name="12047410"></a>Dencker BB, Larsen H, Jensen ES, Schønheyder HC, Nielsen GL, Sørensen HT. Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. <i>Clin Microbiol Infect</i>. 2002;8(4):196-201. doi:10.1046/j.1469-0691.2002.00368.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/12047410/pubmed" id="12047410" target="_blank">12047410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8830011">
<a name="8830011"></a>Garcia LB, Benchetrit LC, Barrucand L. Penicillin post-antibiotic effects on the biology of group A streptococci. <i>J Antimicrob Chemother.</i> 1995;36(3):475-482. doi:10.1093/jac/36.3.475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/8830011/pubmed" id="8830011" target="_blank">8830011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3086721">
<a name="3086721"></a>Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. <i>N Engl J Med</i>. 1986;314(25):1593-1599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/3086721/pubmed" id="3086721" target="_blank">3086721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19246689">
<a name="19246689"></a>Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <i>Circulation</i>. 2009;119(11):1541-1551.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/19246689/pubmed" id="19246689" target="_blank">19246689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28808592">
<a name="28808592"></a>Hawkins KL, Hoffman M, Okuyama S, Rowan SE. A case of fulminant meningococcemia: it is all in the complement. <i>Case Rep Infect Dis</i>. 2017;2017:6093695. doi:10.1155/2017/6093695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/28808592/pubmed" id="28808592" target="_blank">28808592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8497356">
<a name="8497356"></a>Heikkilä AM, Erkkola RU. The need for adjustment of dosage regimen of penicillin V during pregnancy. <i>Obstet Gynecol.</i> 1993;81(6):919-921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/8497356/pubmed" id="8497356" target="_blank">8497356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7955771">
<a name="7955771"></a>Heikkilä A, Erkkola R. Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. <i>Clin Pharmacokinet</i>. 1994;27(1):49-62. doi:10.2165/00003088-199427010-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/7955771/pubmed" id="7955771" target="_blank">7955771</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Heinonen, OP. Sloan D, Shapiro S. Birth defects and drugs in pregnancy. <i>Teratology</i>. 1977;20(3): 487-488.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24447897">
<a name="24447897"></a>Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014;20(2):e130687. doi:10.3201/eid2002.130687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/24447897/pubmed" id="24447897" target="_blank">24447897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8339619">
<a name="8339619"></a>Hsieh MJ, Liu, HP, Chang, JP, Chang CH. Thoracic actinomycosis. <i>Chest</i>. 1993;104(2):366-370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/8339619/pubmed" id="8339619" target="_blank">8339619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27925427">
<a name="27925427"></a>Kanhutu K, Jones P, Cheng AC, Grannell L, Best E, Spelman D. Spleen Australia guidelines for the prevention of sepsis in patients with asplenia and hyposplenism in Australia and New Zealand. <i>Intern Med J</i>. 2017;47(8):848-855. doi:10.1111/imj.13348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/27925427/pubmed" id="27925427" target="_blank">27925427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22123880">
<a name="22123880"></a>Kavanagh PL, Sprinz PG, Vinci SR, et al. Management of children with sickle cell disease: a comprehensive review of the literature. <i>Pediatrics</i>. 2011;128(6):e1552-1574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/22123880/pubmed" id="22123880" target="_blank">22123880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kimberlin.1">
<a name="Kimberlin.1"></a>Kimberlin DW, Brady MT, Jackson MA, Long SS, eds; Committee on Infectious Diseases; American Academy of Pediatrics. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-King.2020">
<a name="King.2020"></a>King KY. Rat bite fever. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3123405">
<a name="3123405"></a>Lindberg RL, Huupponen RK, Viljanen S, Pihlajamäki KK. Ethanol and the absorption of oral penicillin in man. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1987;25(10):536-538.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/3123405/pubmed" id="3123405" target="_blank">3123405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Liszewski.2020">
<a name="Liszewski.2020"></a>Liszewski MK, Atkinson JP. Inherited disorders of the complement system. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31668170">
<a name="31668170"></a>Lockhart PB, Tampi MP, Abt E, et al. Evidence-based clinical practice guideline on antibiotic use for the urgent management of pulpal- and periapical-related dental pain and intraoral swelling: A report from the American Dental Association. <i>J Am Dent Assoc</i>. 2019;150(11):906-921.e12. doi:10.1016/j.adaj.2019.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/31668170/pubmed" id="31668170" target="_blank">31668170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9114201">
<a name="9114201"></a>MacGregor RR, Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. <i>Clin Infect Dis.</i> 1997;24(3):457-467. doi:10.1093/clinids/24.3.457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/9114201/pubmed" id="9114201" target="_blank">9114201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3130891">
<a name="3130891"></a>Matheson I, Samseth M, Løberg R, Faegri A, Prentice A. Milk transfer of phenoxymethylpenicillin during puerperal mastitis. <i>Br J Clin Pharmacol.</i> 1988;25(1):33-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/3130891/pubmed" id="3130891" target="_blank">3130891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23193095">
<a name="23193095"></a>McCavit TL, Gilbert M, Buchanan GR. Prophylactic penicillin after 5 years of age in patients with sickle cell disease: a survey of sickle cell disease experts. <i>Pediatr Blood Cancer</i>. 2013;60(6):935-939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/23193095/pubmed" id="23193095" target="_blank">23193095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28704351">
<a name="28704351"></a>McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(27):734-737. doi:10.15585/mmwr.mm6627e1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/28704351/pubmed" id="28704351" target="_blank">28704351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7691496">
<a name="7691496"></a>Nathwani D, Wood MJ. Penicillins. A current review of their clinical pharmacology and therapeutic use. <i>Drugs</i>. 1993;45(6):866-894. doi:10.2165/00003495-199345060-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/7691496/pubmed" id="7691496" target="_blank">7691496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute (NHLBI). Evidence-based management of sickle cell disease: expert panel report, 2014. Bethesda, MD: National Institutes of Health; 2014. <a href="http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines" target="_blank">http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines</a>. Accessed March 19, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi:10.1161/CIR.0000000000000029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2013;56(1):e1-e25. doi:10.1093/cid/cis803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PenicillinV.1">
<a name="PenicillinV.1"></a>Penicillin V potassium (tablets, USP and Oral Solution, USP) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reboli.1">
<a name="Reboli.1"></a>Reboli AC. Erysipelothrix infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 10, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35049336">
<a name="35049336"></a>Sanyahumbi A, Ali S, Benjamin IJ, et al. Penicillin reactions in patients with severe rheumatic heart disease: a presidential advisory from the American Heart Association. <i>J Am Heart Assoc</i>. 2022;11(5):e024517. doi:10.1161/JAHA.121.024517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/35049336/pubmed" id="35049336" target="_blank">35049336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>, 2012;55(10):e86-e102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9636842">
<a name="9636842"></a>Smego RA Jr, Foglia G. Actinomycosis.<i> Clin Infect Dis</i>. 1998;26(6):1255-1261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/9636842/pubmed" id="9636842" target="_blank">9636842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16231249">
<a name="16231249"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. <i>Clin Infect Dis</i>. 2005;41(10):1373-1406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/16231249/pubmed" id="16231249" target="_blank">16231249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14727221">
<a name="14727221"></a>Sudhaker SS, Ross JJ. Short-term treatment of actinomycosis: two cases and a review. <i>Clin Infect Dis</i>. 2004;38(3):444-447.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/14727221/pubmed" id="14727221" target="_blank">14727221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635049">
<a name="23635049"></a>Thomas KS, Crook AM, Nunn AJ, et al; UK Dermatology Clinical Trials Network's PATCH I Trial Team. Penicillin to prevent recurrent leg cellulitis. <i>N Engl J Med</i>. 2013;368(18):1695-1703. doi:10.1056/NEJMoa1206300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/23635049/pubmed" id="23635049" target="_blank">23635049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238. doi:10.1016/j.bbmt.2009.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Washburn.2015">
<a name="Washburn.2015"></a>Washburn RG. Rat-bite fever: <i>Streptobacillus moniliformis</i> and <i>Spirillum minus</i>. In: Bennett JE, Dolin R, Blaser MJ. <i>Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases</i>. 8th ed. Elsevier; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2017">
<a name="WHO.2017"></a>World Health Organization (WHO). Operational protocol for clinical management of diphtheria. https://www.who.int/publications/i/item/operational-protocol-for-clinical-management-of-diphtheria. Published December 2017. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2004">
<a name="WHO.2004"></a>World Health Organization (WHO). Rheumatic fever and rheumatic heart disease. 2004. Available at http://whqlibdoc.who.int/trs/WHO_TRS_923.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7489869">
<a name="7489869"></a>Wynn RL and Bergman SA, “Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,” <i>Gen Dent</i>, 1994, 42(5):398-402, 498-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/7489869/pubmed" id="7489869" target="_blank">7489869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12004720">
<a name="12004720"></a>Wynn RL, Bergman SA, Meiller TF, et al, “Antibiotics in Treating Oral-Facial Infections of Odontogenic Origin: An Update,” <i>Gen Dent</i>, 2001, 49(3):238-40, 242, 244 passim.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/12004720/pubmed" id="12004720" target="_blank">12004720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2058187">
<a name="2058187"></a>Zhanel GG, Hoban DJ, Harding GK. The postantibiotic effect: a review of in vitro and in vivo data. <i>DICP</i>. 1991;25(2):153-163. doi:10.1177/106002809102500210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-v-potassium-oral-pediatric-drug-information/abstract-text/2058187/pubmed" id="2058187" target="_blank">2058187</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12689 Version 363.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
